Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 12/03/20

Create Access to Targeted Cancer Therapy for -Underserved Populations (CATCH-UP.2020)

Overview/Objectives

Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP.2020) is a congressionally mandated P30 administrative supplement award to eight NCI cancer center support grants to enhance access to targeted cancer therapy for minority/underserved populations. The CATCH-UP.2020 initiative is comprised of eight NCI designated cancer centers that demonstrate robust ability to accrue minority/underserved populations to the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network sponsored precision medicine cancer trials but are not members of the ETCTN’s UM1 program. CATCH-UP.2020 cancer centers are required to accrue a minimum of 24 patients annually to NCI ETCTN trials; in which at least 50% of these patients must belong to a minority/underserved population.

CATCH-UP.2020 Project Leaders

Project Leader Institution (NCI Designated Cancer Center)
Susan M. O’Brien, MD UC Irvine Health
(Chao Family Comprehensive Cancer Center)
Alexandra Thomas, MD Wake Forest University Health Sciences
(Wake Forest Baptist Comprehensive Cancer Center)
Janice Mehnert, MD New York University Langone Health
(Perlmutter Cancer Center)
Joaquina Baranda, MD University of Kansas Medical Center
(University of Kansas Cancer Center)
Amitkumar Mehta, MD University of Alabama at Birmingham
(O’Neal Comprehensive Cancer Center)
Jonathan Trent, MD University of Miami
(Sylvester Comprehensive Cancer Center)
Jason Faris, MD Dartmouth-Hitchcock Medical Center
(Norris Cotton Cancer Center)
Anthony Shields, MD Wayne State University
(Karmanos Cancer Institute)

CATCH-UP.2020 Participating Sites

Lead Academic Organization

  • UC Irvine Health/Chao Family Comprehensive Cancer Center LAO
  • University of Alabama at Birmingham Cancer Center LAO
  • University of Miami Miller School of Medicine-Sylvester Cancer Center LAO
    • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
    • UM Sylvester Comprehensive Cancer Center at Plantation
    • UM Sylvester Comprehensive Cancer Center at Coral Gables
  • Wake Forest University Health Sciences LAO
  • Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center LAO
    • Norris Cotton Cancer Center-North
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone LAO
    • Bellevue Hospital Center
    • NYU Winthrop Hospital
    • NYU Langone Hospital - Brooklyn
  • University of Kansas Cancer Center LAO
    • Ascension Via Christi - Pittsburg
    • HaysMed University of Kansas Health System
    • Olathe Health Cancer Center
    • Salina Regional Health Center
    • Truman Medical Centers
    • University of Kansas Cancer Center - Lee's Summit
    • University of Kansas Cancer Center - North
    • University of Kansas Cancer Center at North Kansas City Hospital
    • University of Kansas Cancer Center-Overland Park
    • University of Kansas Clinical Research Center
    • University of Kansas Health System Saint Francis Campus
    • University of Kansas Hospital-Westwood Cancer Center
  • Wayne State University/Karmanos Cancer Institute LAO
    • McLaren Cancer Institute-Bay City
    • McLaren Cancer Institute-Flint
    • McLaren-Greater Lansing
    • Weisberg Cancer Treatment Center

*LAO = Lead Academic Organization

ETCTN/CATCH-UP.2020 Clinical Trial Portfolio

Study # Document Title
9466 Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only)
9673 A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
9924 A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
9930 A Phase I Trial of MEDI-570 in Patients with Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
9979 Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
10009 A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
10020 A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
10056 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
10057 A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
10089 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
10096 A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)
10100 A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option
10104 A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced Recurrent Metastatic Endometrial Cancer
10107 Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
10129 A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
10144 A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
10146 Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) in patients with metastatic triple negative breast cancer
10150 A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer
10166 A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
10170 A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
10184 Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
10186 A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma
10193 Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
10208 A Phase I study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
10211 A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
10216 A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCI in Patients with EGFR Mutant Non-Small Cell Lung Cancer
10218 A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
10220 A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HC1 in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRG2 and LKB1 Aberrant Tumors
10222 A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors
10240 Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy
10247 A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
10264 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
10276 A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
10287 A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)
10301 A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814 & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
10302 Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
10313 A phase IB and randomized open-label phase II study of M6620 in combination with carboplatin/gemcitabine/avelumab in patients with chemotherapy-naïve advanced non-small cell lung cancer of squamous cell histology
10315 A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
10330 A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
9892 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
10181 A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer
10183 A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma
10191 A Phase 2 study of M6620 in Combination with Carboplatin compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
10204 Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
10266 A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
10268 Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer
10300 BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
10334 BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) who are Ineligible or who Refuse Intensive Chemotherapy
10366 A Phase 1/2 Study of M3814 in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

CATCH-UP.2020 is a one-time supplement; however, once an administrative supplement is awarded, it is anticipated that collaborations will develop between NCI Cancer Centers, local area providers, public health practitioners, and other public health professionals to utilize an NCI Cancer Center’s infrastructure to open ETCTN trials at their clinical sites, to recruit minority/underserved patients to these ETCTN trials, and to provide resources to maintain participation on ETCTN trials until the patient’s endpoint for the trial is achieved.

For more information on the CATCH-UP.2020 initiative, contact Drs. Steven Gore steven.gore@nih.gov or S. Percy Ivy ivp@ctep.nci.nih.gov.